Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A National, Prospective, Non- Interventional Study (NIS) in Patients Receiving Adjuvant Nivolumab Therapy for Resected Melanoma and Subsequent Treatments in Case of Relapse

NCT04550247 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT04550247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04550247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A National, Prospective, Non- Interventional Study (NIS) in Patients Receiving Adjuvant Nivolumab Therapy for Resected Melanoma and Subsequent Treatments in Case of Relapse
Lead sponsor
Bristol-Myers Squibb
Phase
Observational
Overall status
Active, not recruiting
Start date
September 2, 2020
Completion date
March 15, 2027
Enrollment
362 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma